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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) comprises 5.5% of all incidence cancers
and is the sixth leading cancer worldwide with approximately 600,000 cases reported annually
[1, 2]. The vast majority of them are squamous cell carcinomas that originate in the epithelium
of the oral cavity, pharynx and larynx. There is a higher incidence rate in males compared to
females and the median age of patients with HNSCC is about 60 years [3]. The main risk factors
for HNSCC are tobacco smoking and heavy use of alcohol. In particular, alcohol consumption
and tobacco smoking have a synergic effect [4]. The contribution of tobacco exposure to
HNSCC carcinogenesis is strongly correlated with the time and rate of the person who smokes
and has showed to have site-specific differences according to the anatomical regions, with an
increase in sensitivity from the oral cavity down to the larynx [5]. In addition, high-risk
infection types of human papillomavirus (especially HPV-16 and 18) is emerging as a major
cause of a subgroup of HNSCC, particularly those of the oropharynx and oral cavity [2, 6]. The
traditional risk factors, tobacco and alcohol use, do not appear to play a contributing role in
HPV-positive cancers [7]. However, it is known that HPV-positive and negative tumors have
different clinical, pathological and molecular characteristics and that HPV-positive tumors are
associated with a more favorable outcome [2, 6] and better response to standard therapy.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Many molecular studies show that these HNSCC may not be as homogeneous as previously
supposed. This indicates the need to obtain a more detailed molecular characterization in order
to stratify patients better. This ultimately is likely to provide a more rational therapeutic
approach, potentially relevant to diagnosis and prognosis of this poorly defined subset of
HNSCC cancer.
2. Therapy strategies and molecular mechanisms of radioresistance
HNSCC is typically characterized by locoregional diffusion and low propensity to develop
distant metastasis. Due to the lack of symptoms in the early stage of the disease, about two
thirds of patients are diagnosed in advanced stage with lymph node metastases. Local
recurrence affects about 50-60% of patients and metastases develop in 15-20% of cases [8], with
the five-year overall survival rate less than 50% [8, 9]. Locoregional failure is the most common
cause of death in patients affected by HNSCC [10]. Recurrence may arise from residual
neoplastic cells that survive to the treatment or from underlying field cancerization. Indeed,
one key feature of HNSCC is the insurgence of recurrences after seemingly complete surgical
resection, probably due to the existence of preneoplastic processes at multiple sites in the
mucosa (“field cancerization” hypothesis). These preneoplastic tissues are apparently tumor-
free when analyzed at histological level but present several genetic alterations when analyzed
at a molecular level [11, 12].
Typically, HNSCC treatment consists of surgical resection followed by ionizing radiation or
chemoradiation, or chemoradiation alone. Therapeutic strategy choice depends on disease
stage: tumors at early stage are treated with surgery or radiotherapy. Surgery can be performed
if complete tumor excision is possible and radiation can be used postoperatively when surgical
margins are positive for the presence of tumor cells and/or if lymphovascular invasion by
tumor is found. Platinum-based agents, in particular cisplatin (CDDP), are the conventional
chemotherapeutic drugs for HNSCC treatment. More advanced cancers require multimodality
therapy combining surgery, radiation and chemotherapy. Concurrent chemoradiation is the
preferred treatment for advanced inoperable HNSCC [13-15]. These standard therapies have
some limitations; they have several side effects and generally more than 50% of HNSCC
patients relapse. The toxicities are mainly due to non-selective nature of treatment. However,
resistance to chemoradiotherapy frequently occurs and is associated with poor outcome. This
is the major clinical problem in HNSCC patients and relies on the fact that recurrence is often
related to an intrinsic tumor radioresistance [14].
Molecular mechanisms underlying the resistance to radiotherapy or combined treatments
mainly involve intracellular pathways related to cell proliferation, apoptosis, DNA repair and
angiogenesis [13, 14, 16, 17]. To date, the main molecular mechanisms for radioresistance are:
• The hypoxia phenomenon
• Alterations in the Epidermal Growth Factor Receptor (EGFR)- PI3K/Akt pathway
• Epithelial Mesenchymal Transition (EMT) process
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• The deregulation in p53 signaling cascades
• Alterations in the expression of angiogenic factors
• The presence of cancer stem cells (CSCs) subpopulation in tumor tissue
2.1. Hypoxia
Hypoxia is a common phenomenon present in many tumors and is associated with poor
prognosis, malignant transformation and therapy resistance [18, 19]. In solid tumors, including
HNSCC, oxygen is frequently reduced as the result of intermittent blood flow arising from the
abnormal tumor microvasculature. Under oxygen deficiency, hypoxic tumor cells can activate
the expression of hypoxia-inducible genes, functionally related to pro-survival, anti-apoptosis,
angiogenesis, DNA-repair and metabolism signaling pathways [18, 20]. In particular, tumor
cells switch their glucose metabolism from the oxygen-dependent tricarboxylic acid (TCA)
cycle to oxygen-independent glycolysis metabolic pathway; as a consequence, hypoxic cells
use glycolysis as main mechanism to produce ATP.
A key transcription factor having a central role in hypoxia-related gene expression changes is
hypoxia-inducible transcription factor 1 (HIF-1). In normoxia, HIF-1α undergoes rapid
hydroxylation and degradation. In hypoxia, hydroxylation is prevented, stabilized HIF-1α
binds to HIF-1β and the heterodimer binds to hypoxia response elements in target genes, such
as glycolytic enzymes, angiogenic molecules (among which VEGFA), survival and growth
factors (among which EGF, PDGF and TGF-β), chaperons and other apoptosis resistance-
related proteins [13, 18, 21].
DNA double-stranded breaks (DSB) are the main DNA lesions leading to cell killing after
radiotherapy. Oxygen is known to be a potent radiosensitizer and, through interaction with
the radicals formed following radiation, it is essential for the promotion of radiation-induced
DNA damage. Oxygen deficiency causes a reduction in reactive oxygen species (ROS)
production and a deficit in radiation-induced DNA damage [20]. In agreement with these
evidences, cells irradiated in the presence of air are about three times more sensitive than cells
irradiated under conditions of severe hypoxia [22].
One of the evidences linking hypoxia to radiation response is a correlation between tumor
control and hemoglobin levels [23], which is also related to oxygenation of solid tumors.
Indeed, high hemoglobin (Hb) level, prior to and during treatment, has been associated with
good prognosis in HNSCC patients treated with radiotherapy [23].
Hypoxia problem is particularly relevant in smoker patients. Indeed, in these HNSCC patients,
the low oxygen level is also influenced by the formation of carboxyhemoglobin (COHb) and
nicotine vase constrictive effect. As a consequence, the response to treatment and survival of
smoker patients is significantly reduced compared to nonsmokers [23].
Given the influence of hemoglobin on tumor oxygenation and radiotherapy response, many
researches tried to find methods able to increase Hb level in HNSCC patients having low Hb
level, prior to and during radiation treatment; transfusion, or erythropoietin stimulating
agents, are some of them, but unfortunately did not result in improved outcome or response
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to therapy [23]. To date, the main radiosensitizing and cytotoxic agents used in the clinical
practice for hypoxic cells targeting are nitroimidazoles, which have also been shown to
improve locoregional control, when applied in conjunction with radiation [20].
There is also interest in the use of nitroimidazoles as noninvasive hypoxia markers [24, 25].
Indeed, it remains difficult to identify hypoxic tumors and those patients most likely to benefit
from hypoxia modification therapy. Under hypoxic conditions, nitroimidazoles are converted
into reactive intermediates, which then become covalently bound to macromolecules within
the cell. Nitroimidazoles labeling with an appropriate isotope or immunologically recogniza‐
ble marker allows the bioreduced compound to be detected, indicating the presence of
hypoxia.
Additional indirect non-invasive techniques being explored to identify hypoxic tumors
include measuring the immunohistochemical expression of hypoxia-regulated proteins, such
as carbonic anhydrase 9 (CA9) and HIF-1α [26, 27]. This represents an attractive approach for
routine clinical use, but is limited by the variability of expression of these markers within a
tumor and by the lack of hypoxia specificity of individual proteins. An attempt to overcome
these problems has been carried out by searching for tumor hypoxia gene signatures by meta-
analysis of transcriptome datasets [28-30]. Winter and colleagues defined an in vivo hypoxia
metagene by clustering around the RNA expression of a set of known in vitro hypoxia-
regulated genes; this signature was also validated as a prognostic factor for recurrence-free-
survival in an independent data set [30].
2.2. Alterations in the Epidermal Growth Factor Receptor (EGFR)-PI3K/Akt pathway
Epidermal growth factor receptor (EGFR) is a transmembrane protein with tyrosine kinase
activity that is overexpressed in about 90% of HNSCC, even if its expression is highly variable
according to different subgroups of head and neck tumors as well as within the same tumor
type [2, 14]. Stimulation by extracellular soluble ligands as epidermal growth factor (EGF) and
transforming growth factors (TGFs) induces a conformational change leading to receptor
heterodimerization with one of its family members (ErbB2, ErbB3, ErbB4); this causes auto‐
phosphorylation of the receptor intracellular domain and subsequent internalization followed
by the activation of multiple signaling pathways, such as Ras-MAPKs (mitogen-activated
protein kinases), extracellular signal-regulated kinases (ERKs), phosphatidylinositol-3-kinase-
AKT (PI3-K/AKT), signal transducers and activators of transcription (STAT) and phospholi‐
pase C gamma (PLC-g) pathways [20].
High EGFR expression correlates with poor prognosis and resistance to conventional radio‐
therapy. EGFR expression can also be activated by the ionizing radiation itself, leading to
increased radioresistance [20]. EGFR activation is also involved in increased proliferation rate
and consequent repopulation, rendering radiotherapy ineffective [14].
Key proteins activated by EGFR are AKT and Ras; the first one is a kinase which phosphory‐
lates multiple downstream effectors, stimulating cell survival and inhibiting apoptosis; Ras is
a cell membrane protein able to stimulate a tyrosine kinase cascade, including B-RAF, MEK,
MAPK proteins, by which Myc, FOS and Jun translocate in the nucleus finally promoting cell
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proliferation. This cascade is also able to stimulate the production of EGFR monomers, TGFs
and amphiregulin (AREG), contributing to paracrine EGFR activation [14]. Other proteins
activated by EGFR are cyclin D1 and Pim-1, involved in cell cycle progression and inhibition
of apoptosis; for the activation of both, the signal is mediated by STATs proteins [31, 32]. In
addition, the interaction between EGFR-PI3-K/AKT and HIF pathways was also observed
under hypoxic conditions, providing evidences on the correlation between EGFR signaling
and the induction of angiogenic proteins, such as VEGFA, which is a downstream target of
HIF-1 [20]
A subgroup of HNSCC (40%) expresses a truncated splicing variant of the EGFR, called
EGFRvIII, in which the ligand-binding domain is altered, due to the deletion of amino acids
6-273. This alteration causes a permanent phosphorylation and activation of the receptor, also
in the absence of EGF and TGFs ligands binding. As wild-type EGFR, EGFRvIII is implicated
in increased cell proliferation, cell survival, motility and invasion. This variant is absent in
normal tissues [17].
Besides EGFR overexpression, other mechanisms are involved in PI3K/Akt signaling hyper-
activation, such as Ras activation, PI3-K gene mutation, Akt gene amplification and loss of
tumor suppressor protein PTEN [14].
2.3. Epithelial Mesenchymal Transition (EMT) process
Another important mechanism by which radiotherapy can fail in HNSCC is epithelial to
mesenchymal transition (EMT) process. When EMT occurs, epithelial cells change in mesen‐
chymal phenotype which is characterized by reduction of the matrix contact, cell–cell adhesion
followed by an increase in cell migration and motility. A crucial step of EMT is the loss of E-
cadherin, a strong epithelial marker involved in adherens junction that anchors epithelial cells
to each other [33]. A reduction of E-cadherin level was observed in HNSCC, especially in poorly
differentiated tumors. In addition, many studies have demonstrated that aberrant E-cadherin
expression is associated with poor outcome and local recurrence in HNSCC [34]. Loss or
decrease of E-cadherin expression causes the translocation of β-catenin protein from the cell
membrane to the nucleus to induce transcription of EMT-related genes, such as TWIST and
SNAIL1 [33]. Another important protein involved in EMT is vimentin, which is an intermediate
filament protein used as a marker for mesenchymal cells and is associated with the migratory
phenotype, local recurrence and survival in HNSCC [34, 35]. Also fibronectin, a glycoprotein
which mediates cellular interaction with extracellular matrix, plays an important role in
migration, growth and adhesion of cells; its expression can be promoted by SNAIL and TWIST
transcription factors [33]. Fibronectin is expressed at high level in tumors and blood plasma
of HNSCC patients and has been proposed as biomarker of poor response to radiotherapy [36].
2.4. TP53 gene deregulation
TP53 is a tumor suppressor gene, which functions in carcinogenesis by initiating G1 arrest in
response to certain DNA damages and apoptosis. About 40-70% of HNSCC has mutation in
TP53 gene, leading to inactivation of its product [37]. Indeed, mutant p53 proteins are unable
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to transcriptionally regulate wt-p53 target genes and to exert antitumor effects such as
apoptosis, growth arrest, differentiation and senescence. On the other hand, countless
evidence has demonstrated that at least certain mutant forms of the p53 protein may possess
gain of function activity, thereby positively contributing to the development, maintenance and
spreading of many types of tumor, including HNSCC [38, 39]. The prognostic role of p53
alteration in HNSCC is controversial. However, generally, deregulation of p53 protein predicts
shorter overall survival, local recurrence and cancer treatment failure [40-44].
In particular, p53 alteration leads to an impaired capability to arrest cell cycle and to inhibit
apoptosis. In addition, in this condition also DNA damage repair results compromised. As
a consequence, tumor cells carrying TP53 mutation are less sensitive to radiation-induced
cell  death  and  are  unable  to  restore  DNA  integrity,  thus  accumulating  several  genetic
mutations  which  lead  to  increased  tumor  heterogeneity  and  finally  to  resistance  to
conventional therapy [14].
In addition, several evidences show that its prognostic value depends on the TP53 protein
domain affected by mutation [43-46]. One of the main classifications of TP53 mutation used in
HNSCC is “disruptive” versus “not-disruptive”; any mutation in L2 or L3 loop of the DNA-
binding domain resulting in a polarity change of the protein or any stop codon was classified
as disruptive [44]. Disruptive TP53 mutations were associated with poor outcome and
increased radioresistance [44, 46]. Other studies have proposed an alternative classification by
which mutations in DNA-binding regions, especially in L2 and L3+LSH motifs, were associ‐
ated with poorer prognosis and clinical response to radiotherapy [45].
Of note, emerging evidences show that senescence may play a role in the radiation response
by wild-type p53 [47]. Senescence is a form of cell cycle arrest in which cells lack replicative
potential while remaining metabolically active, and was found to correlate with radiosensi‐
tivity in HNSCC [46]. In the proposed model, in the presence of TP53 wild type or nondis‐
ruptive mutation, radiation promotes the induction of ROS production and p21 protein
expression, which are critical mediators of cellular senescence. TP53 disruptive mutations
cause cellular senescence inhibition by reduction of radiation-induced ROS, thus driving
resistance to radiotherapy [46].
2.5. Alterations in the expression of angiogenic factors
Angiogenesis is a process by which new blood vessels grow up from preexisting capillaries.
Because expanding tumors have a continuous need for oxygen and nutrients, tumor cells
induce angiogenesis. In particular, by secreting a variety of growth factors they activate the
endothelial cells, constituting the inner lining of blood vessels, which produce proteases that
degrade the basal membrane and extracellular matrix components. As a consequence, the
endothelial cells can proliferate and migrate forming new capillary beds. Because in tumors
new blood vessels are irregular and disorganized, the oxygen supply inside the tissue is not
homogenous, resulting in continuous angiogenesis stimulation [48].
The main actors of this process are vascular endothelial growth factor (VEGF), fibroblast
growth factor (FGF) and matrix metalloprotease (MPP) family proteins.
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VEGF family consists of seven ligands, which play a central role in the formation of new blood
vessels; VEGFA is the best known agent that induces angiogenesis by binding two receptor
tyrosine kinases, VEGFR-1 and VEGFR-2. VEGFA is able to promote development of the
vascular system, cell migration, survival and induction of MMPs [13]; it also activates
PI3K/AKT and Ras/MAPK signaling pathways [49]. There are increasing evidences that
angiogenic response of irradiated tumor cells is related with decreasing radiation sensitivity
and head and neck cancer progression. In a meta-analysis of 12 studies including 1002 patients
affected by cancer of oral cavity, pharynx and larynx, VEGF expression positivity was
associated with a two folds higher risk of death at 2 years of follow-up [50].
Release of VEGF and bEGF by epithelial tumor cells after irradiation is a common response
mechanism by which cancer cells may survive and become protected from radiation-induced
cell death [51]. Therefore, the level of VEGF and bEGF prior to and during treatment may be
relevant for successful therapy.
2.6. Cancer Stem Cells (CSCs)
Cancer stem cells (CSCs) have been defined by Clarke et al., as a small tumor subpopulation
possessing the capability to self-renewal and causing the heterogeneous lineage of cancer cells
inside the tumor [52]. They are functionally defined as a subset of tumor cells with ability of
self-renewal and multipotency, serving as progenitors of cancer cells. The characteristics by
which CSCs can be distinguished to other cancer cells are the following [53]:
1. Promotion of tumorigenesis when they are transplanted in immunosuppressed mice.
2. Expression of specific cell surface markers (such as CD44, CD133, ALDH1, CD24) and
formation of tumor spheres.
3. Tumors arising from CSCs have a heterogeneous cells population composed by tumori‐
genic and non-tumorigenic cells.
4. Capacity of self-renewal in seriated transplants over several generations.
The presence of this subpopulation has been identified in several tumors, including HNSCC
where its ability to maintain tumor population, metastasize and to be resistant to radioche‐
motherapy has been shown [53-55].
The origin of CSCs has not been clearly defined; in HNSCC, it has been proposed that a chronic
inflammation caused by permanent tobacco, alcohol use, mechanic irritation or viral infection,
in association with genetic predisposition, lead to the accumulation of various genetic
alterations and finally to the manifestation of a malignant phenotype [53].
In addition, during tumor progression, some CSCs, through an EMT process, can acquire the
ability to infiltrate and metastasize. On the other hand, EMT is involved in the acquisition of
cancer stem cells properties; at the molecular level, the transcription factor Twist induces
downregulation of E-cadherin while promoting expression of Bim1, which has an essential
role in self-renewal of CSCs. In agreement with these data, high expression of Bim1 and Twist
are associated with a poor prognosis in HNSCC [53].
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In HNSCC patients, high percentage of CD44 positive cells was associated with higher rate of
treatment failure in general, while cells expressing CD44, CD24, Oct4 and integrin β1 were
associated with poor outcome after radiotherapy [56, 57]. From a clinical point of view, these
evidences suggest that the patients can be cured if CSCs are completely eliminated.
3. Potential molecular markers for local recurrence and radioresistance
One of the current major research questions in the management of HNSCC disease addresses
the prediction and treatment of local recurrence. As described before, mortality of patients
with HNSCC is primarily driven by tumor cell radioresistance leading to local recurrence. Due
to the heterogeneous nature of tumors, the identification of markers with prognostic or
predictive value to be used as a complement to conventional diagnostic methods is a complex
challenge. Indeed, although advance in expression technologies, current studies have provid‐
ed ambiguous results.
Among the prognostic markers proposed in HNSCC, as described in the previous paragraph,
the presence of mutation in TP53 gene predicts the development of locoregional recurrence by
increasing the radioresistance in tumor cells (Table 1).
Additional molecular markers predicting high local recurrence development and response to
radiotherapy are summarized in Table 1.
Gene Function References
TP53 A tumor-suppressor regulating cell cycle progression, apoptosis andcell survival. [2, 42, 44, 46, 58]
HIF-1α A transcription factor induced under hypoxic condition andpromoting EMT, angiogenesis, cell migration and metastasis. [16]
PTEN A tumor suppressor gene regulating signaling pathways controllingcell proliferation and apoptosis. [59-62]
Fibronectin It is a glycoprotein of the extracellular matrix, which plays a majorrole in cell adhesion, growth, migration, and differentiation. [36]
EGFR
Transmembrane TK acting as a central transducer in multiple
pathways that mediate cell cycle progression, angiogenesis,
inhibition of apoptosis, tumor invasion and metastasis.
[14, 20]
VEGFs Ligands of transmembrane TK promoting cell proliferation,migration and survival of endothelial cells during tumor growth. [13, 14, 20, 51]
Cox2 Catalytic enzyme decreasing apoptosis, increasing inflammationand important for tumor progression. [63]
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Gene Function References
p-AKT (Ser473)
It is a serine/threonine-specific protein kinase that plays a key role in
multiple cellular processes such as glucose metabolism, apoptosis,
cell proliferation, transcription and cell migration.
[64]
Cyclin B1
It is a regulatory protein involved in mitosis. It begins to increase
during G2, peaks in mitosis, and is rapidly degraded before the cell
cycle is completed. By the interaction with cdk1, cyclin B1 promotes
cell progression.
[65, 66]
E-cadherin/
Vimentin
They are protein markers of EMT; E-cadherin is a marker of
epithelial cells, while vimentin is a marker of mesenchymal cells. [34, 35]
Yap/BCL-2/
c-met/VEGF/ Clauding
They are genes involved in cell proliferation, migration, inhibition of
apoptosis and angiogenesis. [67]
Rac1
It is a member of Rac family of Rho GTPase involved in intracellular
adherens junction, epithelial differentiation and regulation of
motility.
[68, 69]
Pim-1
It is an oncogene with serine/threonine kinase activity mainly
involved in cell cycle progression, apoptosis and transcriptional
activation.
[32]
CD10 Cell surface antigen associated with CSCs. [70]
FOXM1 It is a gene involved in cell cycle regulation, which is associated withradioresistance only in quiescent cells. [71]
15–gene hypoxia classifier
composed by ADM,
ALDOA, ANKRD37,
BNIP3, BNIP3L, C3orf28,
EGLN3, KCTD11, LOX,
NDRG1, P4HA1, P4HA2,
PDK1, PFKFB3, SLC2A1
These genes are able to classify more or less hypoxic tumors.
Tumors classified as high hypoxic and treated with radiotherapy
show a poor outcome respect to low hypoxic ones. Accordingly,
more hypoxic tumors have a better response to radiosensitiser
nimorazole respect to those classified as low hypoxic.
[29]
Gene expression model of
intrinsic tumor
radiosensitivity based on
the expression of 10 genes
composed by Androgen
Receptor (AR), c.Jun,
STAT1, PKC, RelA, c-Abl,
SUMO-1, CDK1 (p34),
HDAC1, IRF1
The authors developed a radiosensitive predictive model using 10
genes comprised in central pathways involved in radioresistance.
This linear regression algorithm generates a radiosensitive index RSI
having a prognostic value in HNSCC datasets.
[72]
Table 1. Biomarkers predicting local recurrence and radioresistance in head and neck cancers.
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3.1. MicroRNAs as new potential biomarkers predicting radiotherapy response
A class of small non-coding RNAs termed microRNAs (miRNAs) has recently been indicated
as biomarker of some type of cancers [73]. miRNAs are endogenous, small, non-coding RNAs
of 17-25 nucleotides that are thought to regulate approximately 30% of human genes at
posttranscriptional level, primarily through their partial complementarity with the coding
region or 3’ untranslated region (UTR) of target mRNAs. This leads to translational repression
and/or degradation of target mRNA, therefore regulating gene expression [74]. They are
involved in essential biological activities such as cellular differentiation, proliferation,
development, apoptosis and cell cycle regulation. The roles of miRNAs in cancer have been
extensively investigated in the past few years. The relevance of miRNAs in cancer was
suggested by the observed changes in expression patterns and recurrent amplification as well
as deletion of miRNA genes in cancer [75]. It has been shown that there are two types of cancer-
related miRNAs: oncogenic or tumor suppressor miRNAs [74].
Several investigators have empathized the role of miRs as biomarkers for HNSCC [42] and the
usefulness of miRs as prognostic factors has only begun to be explored. Moreover, miRNA
expression may predict the efficacy of therapies, including radiotherapy [76]. Data from the
study of miR-205 and let-7d expression showed their association with locoregional occurrence
and shorter survival [77]. In addition, high expression of miR-205 can be used to detect positive
lymph nodes, suggesting that this miR can be considered as a marker for metastatic HNSCC
[78]. A similar study has shown that lower expression levels of miR-451 in HNSCC tumors are
associated with recurrence [79]. Another recent work reported that downregulated miR-125b
expression was associated with proliferation and radioresistance mechanisms, probably
through ICAM2 signaling [80]. In addition, miR-17-5p expression has been shown to be
induced in irradiated oral cancer cells and it downregulates p21 protein expression, contribu‐
ting to radioresistance [81].
Furthermore, we also identified microRNAs signatures (miR-17-3p, miR-18b-5p, miR-324-5p,
miR-19a-3p, miR-200a-3p, miR-331-3p, miR-21-3p, miR-21-5p, miR-205-5p, miR-151a-3p,
miR-96-5p and miR-429) that are able to predict the risk of local recurrence and poor outcome
in HNSCC tumors, and that are more powerful as biomarkers when compared to traditional
prognostic indicators [42]. Finally, some evidences support the possibility to use miRNA
detected in plasma as radio-responsive biomarkers for different types of cancer, including
HNSCC. Accordingly, in HNSCC patients, the authors have detected changes in the abun‐
dance of circulating miRNAs (miR-425-5p and miR-93-5p) during radiochemotherapy. In
addition, the researchers have demonstrated that the altered plasma miRNA changes after the
therapy are the results of miRNAs release from damaged tumor cells [82].
4. Molecular strategies and future application in the treatment of HNSCC
Conventional HNSCC treatment consists of surgical resection followed by ionizing radiation
or chemoradiation. In case of local advance/inoperable HNSCC, the typical treatment is
concomitant platinum-based chemoradiotherapy. These standard therapies have some
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limitations; the surgery can result in disfigurement and functional impairment, while the
radiochemotherapy, although it is an organ-preserving treatment, can cause several side
effects including mucositis, oral candidiasis, loss of taste, xerostomia and osteoradionecrosis
[83, 84]. In addition, overall five-year survival rate is lower than 50% in HNSCC patients.
Therefore, resistance to chemoradiotherapy often occurs and is associated with recurrences
and poor outcomes; this represents a major clinical problem for HNSCC patients [14].
The understanding of the molecular perturbations in the cells of carcinomas recurring after
irradiation could help to identify more specific target proteins and design novel therapeutic
agents that will help improving therapy outcome in patients with HNSCC recurrences.
Tumor cells repopulation is a common effect observed in radiotherapy failure. A method to
decrease this phenomenon, called Accelerated Radiotherapy (AR), is the reduction of overall
radiation treatment time maintaining the total dose constant [14]. This therapeutic approach
has produced excellent results in patients with advanced HNSCC [85]. In addition, several
studies have shown that patients overexpressing EGFR protein, result to be more sensitive and
consequently to have a better response to AR [14].
Besides the modification of radiotherapy modalities, there are several therapeutic strategies,
such as, for example, immunotherapy, that can be combined with radiation, and are subjected
to clinical development [86] (Table 2). Currently, two of the main intriguing targets for new
targeted therapy are EGFR and VEGFR [86]. Both targeted therapies can be subdivided in
monoclonal antibodies and tyrosine kinase inhibitors.
4.1. EGFR targeted therapy
The role of EGFR signaling in radioresistance was widely discussed in the paragraph 2.2. Many
evidences suggest that the use of EGFR inhibitors in combination with radiotherapy improves
the outcomes of HNSCC patients respect to those treated with radiotherapy alone [14].
4.1.1. EGFR monoclonal antibodies
One of the main antibodies targeting EGFR is called cetuximab. Other anti-EGFR antibodies
under active investigations in combination with chemoradiotherapy in HNSCC are panitu‐
mumab, zalutumumab and nimotuzumab (Table 2).
Cetuximab: It is a chimeric IgG1 mAb, which by the recognition of determinants expressed on
the extracellular domain of EGFR, antagonize normal receptor interaction, preventing the
activation of the downstream signaling pathways [17]. Based on the results obtained from the
clinical trials, since 2006 it has been approved by the Food and Drug Administration (FDA) in
association with radiotherapy [14, 86]. However, a meta-analysis studying 15 trials and
focusing on the comparison of the two currently combined modality therapies show that
chemoradiotherapy respect to radiotherapy plus cetuximab is associated with a better overall
survival and locoregional recurrence in advanced HNSCC [87]. In addition, some HNSCC
patients develop a resistance to anti-EGFR therapy mainly due to k-Ras deregulation in
absence of its mutation [14, 17, 88] and the presence of the variant EGFRvIII in tumor cells [17].
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In this last case, the deletion presents in this variant cause a reduction in the binding affinity
of monoclonal antibodies raised with wild type EGFR [17].
Panitumumab: Preclinical evidences show that it increases radiosensitivity by the radiation-
induced DNA damage and preventing the translocation of EGFR in the nucleus. Currently,
therapy combining radiation in combination with panitumumab is undergoing phase III
clinical trials [86]. In addition, a phase III trial performed in advanced HNSCC patients to
compare 5-FU and cisplatin treatment in presence and not of panitumumab have not shown
an important improvement of the clinical outcome [89].
Zalutumumab: Several studies on phase I/II trial were performed using this drug at different
doses in combination to radiation and/or chemotherapy; the results are encouraging and a
phase III is ongoing [86].
Nimotuzumab: Preclinical studies show that it has antiproliferative, antiangiogenic and
proapoptotic effects and it is well tolerated in HNSCC patients treated with radiation [86].
However, it has been demonstrated that cetuximab is more effective in comparison to nimo‐
tuzumab in enhancing radiosensitivity in high-EGFR expressing cells [90].
In conclusion, antibody anti-EGFR in combination with radiation therapy was well tolerated
in HNSCC patients; currently, the best-studied mAb are cetuximab and panitumumab. Both
improve radiosensitivity and overall survival in advanced HNSCC treated with radiation.
However, the addition of cetuximab to conventional chemoradiotherapy has not shown a
significant improvement in clinical outcome and the results obtained from the treatment of a
large number of patients in multi-centered trials has shown that the treatment is effective in
about 20% of cases [17].
To date, the use of cetuximab in combination with radiation represents a standard clinical
approach, particularly in HNSCC patients who cannot tolerate chemotherapy [86].
4.1.2. EGFR tyrosine kinase inhibitors
Another group of agents targeting EGFR are small molecule tyrosine kinase inhibitors (TKIs).
They act preventing EGFR autophosphorylation and consequently its activation by the
occupation of the EGFR intracellular ATP-binding domain [17]. The two best studied TKIs are
gefitinib (Iressa) and erlotinib (Tarceva). Others are called lapatinib and afanitib (Table 2).
Gefitinib: Preclinical studies show that gefitinib treatment on HNSCC cells can inhibit cell
proliferation, decrease cell survival and enhance tumor cell radiosensitivity [91]. In addition,
encouraging results were obtained in the clinical studies when gefitinib was combined with
VEGFR inhibitors or other targets, suggesting the possibility to use it as possible neoadjuvant
agent. Besides that, clinical trials combining gefitinib with chemoradiotherapy have not yet
demonstrated a significant improvement respect to conventional therapy [86].
Erlotinib: Encouraging results were obtained from preclinical studies showing that the
combination of erlotinib with radiation and/or VEGFR inhibitors improve treatment efficacy
by the inhibition of tumor growth, proliferation and vessel density [92, 93]. However, to date,
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there is no convincing clinical evidence that the addition of erlotinib to conventional therapy
is universally beneficial [86]
Lapatinib and Afatinib: They are orally active EGFR and HER2 inhibitors, which seem to be well
tolerated from HNSCC patients. Interestingly, in p16-negative HNSCC patients, a large
difference in clinical outcome was observed in patients treated with lapatinib versus placebo.
Phase III trials are ongoing in HNSCC for both molecules [86].
4.2. VEGF targeted therapy
As explained in the paragraph 2.5, VEGF is one of the most important regulators of angiogen‐
esis; its upregulation is a common event in HNSCC and it is associated with radioresistance
and poor prognosis.
4.2.1. VEGF monoclonal antibodies
Bevacizumab (Avastin) (Table 2) is the main recombinant anti-VEGFA monoclonal antibody
under active investigation for HNSCC therapy. Preclinical evidences show that bevacizumab
is able to act as radiation sensitizer in HNSCC cells, to reduce angiogenesis and tumor growth
[86]. Phase I/II clinical trials performed using bevacizumab in combination with conventional
chemoradiotherapy in HNSCC have shown that although this combined modality therapy is
possible, to date there is no strong evidence that the addition of bevacizumab to chemoradio‐
therapy causes an improvement of the overall survival in HNSCC patients [13]. Future
investigations are necessary to define the effectiveness of this molecule in the treatment of
HNSCC.
4.2.2. VEGFR tyrosine kinase inhibitors
To date, the known VEGF tyrosine kinase inhibitors are: vandetanib (ZD6474), sunitinib,
sorafenib and linifanib (ABT-869) (Table 2).
Vandetanib: It is an orally multi-kinase inhibitor targeting EGFR, VEGFR-2 and RET tyrosine
kinases. Preclinical evidences show that the administration of vandetanib enhances the
antitumor effects of radiation therapy by inhibition of both EGFR and VEGFR signaling in
HNSCC human tumor xenografts; in particular, the authors demonstrate that radiation plus
vandetanib treatment is effective in both overexpressing EGFR tumor cells and EGFR- null
cells [94]. In addition, vandetanib restores HNSCC cells sensitivity to cisplatin and radiation
in vivo and in vitro by promoting an increase of apoptosis and a decrease of microvessel density
[95]. A randomized phase II clinical trial using a combination of cisplatin and radiation with
or without vandetanib in advanced HNSCC is under consideration [13].
Sunitinib: It is an orally multi-kinase inhibitor targeting VEGFR, PDGFR and c-Kit tyrosine
kinases. Preclinical and clinical studies show that sunitinib has low activity as monotherapy,
but in combination with cetuximab and radiation, it causes a strong tumor inhibition effect by
a complete abolition of tumor growth. Specifically, the combination of cetuximab and sunitinib
causes a decrease of cell proliferation and enhances cell differentiation, while a decrease in
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tumor vessels number was observed when the radiation treatment was added [96]. These
results encourage future clinical investigations regarding the sunitinib and chemoradiother‐
apy treatment combination.
Sorafenib: It is an oral inhibitor of serine/threonine protein kinase b-Raf, C-Raf, VEGFR and
PDGFR. Preclinical evidences show that sorafenib in combination with chemoradiation is able
to enhance a more effective antitumor effect by the inhibition of cell growth, clone formation,
cell migration and invasion compared to chemoradiation or radiation alone. This therapy
combination is also able to inhibit tumor angiogenesis [97]. In addition, sunitinib can increase
the antiproliferative effect of chemoradiotherapy by inhibiting the Raf/MEK/ERK signaling
pathway and consequently downregulating the expression of the DNA repair proteins ERCC-1
and XRCC-1 [13]. Although these results suggest that sorafenib could enhance the effectiveness
of chemoradiotherapy, ongoing phase I/II clinical trials will determine the real efficacy of
sorafenib in HNSCC patients.
Linifanib: It is a novel ATP-competitive tyrosine kinase inhibitor of the VEGF and PDGF
receptor family members. Preliminary data on HNSCC cells show that linifanib can act as
radiation sensitizer since its combination with radiation is more effective compared to
radiation or chemoradiation alone [13].
4.3. Other targeted therapies
As explained in the paragraph 2 relative to molecular mechanisms of radioresistance, there
are many actors playing a key role in the failure of radiotherapy in HNSCC. As a consequence,
targeted therapies against other molecules besides EGFR and VEGF family proteins were
developed and their characterization is still ongoing. Among them, there are Src-family kinase
inhibitors such as dosatinib; proteasome inhibitors as bortezomib, cyclooxygenase(Cox)-2
inhibitor (colecoxib); PI3K/Akt/mTOR inhibitors as wortmannin, perifostine and temsiroli‐
mus; and therapies targeting c-Met signaling pathway [14, 86] (Table 2).
Briefly, Src-kinase inhibitor dasatinib promotes radiosensitization by decreasing EGFR
phosphorylation, its translocation in the nucleus and consequently, its association with DNA–
protein kinases, blocking DNA repair pathways [98, 99]. Evidences on proteasome inhibitor
bortezomib show its capability to act as radiosensitizer; specifically, it promotes the upregu‐
lation of PTEN activity and downregulation of p-Akt, leading to an increase of apoptosis of
tumor cells [100-102]. Cox inhibitor colecoxib leads to a decrease of VEGFR expression and
angiogenesis [103]. Next, mTOR inhibitors cause a reduction of angiogenesis and an induction
of cell death by autophagy [86, 104]. Finally, given the important role discussed in the
paragraph 2 on the significance of CSCs subpopulation in radioresistance, an emerging concept
is the combined use of standard chemoradiotherapy with cancer stem cells targeted therapy.
Preclinical study on CD44 expressing HNSCC cells combine radiation with anti-CD44
antibodies; the results show an increase in local tumor control in patients treated with radiation
plus anti-CD44 antibodies compared to those treated with radiation alone in vivo [105].
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Anticancer Agent Type of agent Target of Agent Phase of development in HNSCC
Cetuximab mAb IgG1 EGFR Approved by FDA, phase III/IV
Panitumumab mAb IgG2 EGFR Phase III
Zalutumumab mAb IgG1 EGFR Phase III
Nimotuzumab mAb EGFR Phase III
Gefitinib TKI EGFR Phase I/II
Erlotinib TKI EGFR Phase I/II
Afatinib TKI EGFR/HER2 Phase III
Lapatinib TKI EGFR/HER2 Phase III
Bevacizumab mAb VEGFA Phase III
Vandetanib TKI VEGFR/EGFR Phase I
Sunitinib TKI VEGFR/PDGFR/kit Phase I
Sorafenib TKI VEGFR/PDGFR/Raf Phase I
MM-121 mAb IgG2 HER-2 Preclinical phase
Pertuzumab mAb IgG1 HER-3 Preclinical phase
AV-203 mAb IgG1 HER-3 Phase I
RO5479599 mAb HER-3 Preclinical phase
Motesanib TKI VEGFR/PDGFR/kit Preclinical phase
Dasatinib TKI Src family kinase Phase I/II
Bortezomib Proteasome inhibitor 26S proteasome Phase I
Celecoxib Nonsteroidalanti-inflammatory inhibitorCox-2 Phase I
Everolimus Inhibitor derived fromrapamycin mTor Phase I
Temsirolimus Inhibitor derived fromrapamycin mTor Phase I
Onartuzumab mAb c-Met Preclinical phase
Cixutumumab mAB IgG1 IGFR Phase 0/II
Ficlatuzumab mAb IgG1 HGF Phase I
AMG 102 mAb IgG2 HGF Preclinical phase
Fresolimumab mAb IgG4 TGF-β Preclinical phase
Table 2. List of molecular targeted therapies combined with radiotherapy under consideration for treatment of
HNSCC patients (clinicaltrials.gov) [13, 86, 106].
4.4. Therapy by reactivation or elimination of mutant p53 protein
The vast majority of HNSCC show mutations in TP53 gene; several evidences have shown that
mutant p53 protein loses its function as tumor suppressor and acquires new oncogenic
functions by which it promotes resistance to cisplatin and radiation treatment. The transfection
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of wild-type TP53 into cell lines induces growth arrest and reduces tumorigenicity in nude
mice. This suggested that restoring p53 function in HNSCC could inhibit cell growth [107].
HNSCC has been one of the first tumor localities to benefit from gene transfer therapy. Several
strategies have been developed to restore p53 function in HNSCC [14, 108].
Gene therapy: The most used vector for p53 gene therapy in HNSCC is the adenovirus, for its
high affinity with the cells of the upper aerodigestive tract. A series of modified p53 adenovi‐
ruses (Ad-p53) are able to induce apoptosis and sensitize HNSCC cells to radiotherapy [109,
110]. Therefore, a phase I/II clinical trial based on the injection of Ad-p53 in HNSCC patients
was performed and has shown that Ad-p53 is a promising therapeutic strategy [111, 112]. A
phase III study based on the comparison of Ad-p53 to methotrexate treatment in advanced
HNSCC show that overall, there is no significant difference in clinical outcome between these
two subgroups of treated HNSCC, but, interestingly, Ad-p53 treatment was associated with a
significant increase of survival in specific subgroup of HNSCC patients, having TP53 wild type
but inactivated by the upregulation of p53 inhibitors Mdm-2 or Mdm-4 [113]. This evidence
suggests the possibility to select HNSCC patients who are most likely to benefit from Ad-p53
therapy. Another phase III clinical trial based on the use of recombinant Ad-p53 (gendicine)
injection in combination with radiation shows encouraging results [114].
Virus targeting p53 deficient cells: This therapeutic strategy is based on the elimination of
mutant p53. The efficient replication of adenovirus requires the neutralization of p53 function
through E1B viral protein. ONYX-015 is an engineered adenovirus that does not express E1B
protein and consequently is able to induce viral replication and cell death only in tumor cells
carrying TP53 mutations. Phase I/II clinical trials performed in HNSCC patients have shown
that intravenous administration of ONYX-15 is feasible and while the treatment with ONYX-15
alone gave only marginal effects, its combination with cisplatin and 5-fluorouracil had a more
profound impact on the response of patients [115]. Other clinical trials will be necessary to
evaluate its real effectiveness in HNSCC treatment.
Molecules reactivating mutant p53: They are small molecules able to alter the conformation
of mutant p53 to wild type, leading to the restoration of its tumor suppression function. Among
them, glycerol treatment is able to reactivate p53 wild-type functions in HNSCC cell lines
carrying mutant p53 by its ability to refold proteins [116]. Due to its toxicity, glycerol use is
not so feasible in HNSCC patients. As a consequence, a series of other similar molecules was
developed. Among them, PRIMA and CP-31389 were tested in HNSCC cell lines carrying
mutant p53 and have demonstrated to inhibit proliferation and promote apoptosis by the
induction of p53-related genes expression, including p21, Bax, Puma and Noxa [117]. Cur‐
rently, there are no clinical data testing real effectiveness of these molecules in the treatment
of HNSCC patients.
Molecules disrupting p53 inhibitors: In tumor cells, the function of p53 protein can be
compromised not only by the presence of mutation on its gene, but also by upregulation of its
inhibitors. The main p53 natural inhibitor is MDM2, which functions binding p53 protein and
promoting its degradation. Nutlins and their derivate RITA are a class of small molecules able
to prevent the binding MDM2-p53, restoring p53 tumor suppressor function. Therefore,
Nutlins and RITA treatment leads to an increase of nuclear p53 levels, inhibition of prolifera‐
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tion, increase of cell death and antitumor efficacy of cisplatin [108]. Therapy treatment based
on these molecules is more effective in tumor cells carrying p53 wild-type compared with
mutant p53-carrying cells.
In addition, in a subset of HPV-related HNSCC, the activity of p53 can be also inhibited by the
exogenous viral oncoprotein E6. Specifically, it acts by interacting with E6AP protein to
degrade p53 via proteasome pathway and with p300 to prevent p53 acetylation. Treatment of
HNSCC cell lines with the small molecule CH1iB, disrupting the binding of E6 HPV16 protein
and p300, promotes an increase of the p53 acetylation levels and therefore an increase of p53
transcriptional activity. Additionally, Ch1iB shows an anticancer effect also due to its capa‐
bility to reduce cancer stem cells population and by sensitizing tumor cells to cisplatin
treatment in HPV positive cells [14, 108].
4.5. microRNAs as therapeutic agents
The role of microRNAs as predictors and modifiers of chemoradiotherapy in several kinds of
human cancers, including HNSCC, has been shown [118]. For instance, miR-125b transfection
on oral cancer cell lines enhances radiosensitivity to X-ray irradiation [80]. In addition, changes
in the abundance of circulating miRNAs during radiochemotherapy has been detected and
has been shown to reflect the therapy response of primary HNSCC cells after an in vitro
treatment [82]. Finally, in our laboratory, we have demonstrated that the expression of
signatures of TP53 mutation-associated miRNAs, composed of 12 and 4 miRNAs, predicts,
respectively, the risk of local recurrence insurgence and poor outcome, independently from
other relevant prognostic indicators [42]. These evidences suggest the possibility of monitoring
changes in miRNAs expression before to and during treatment in order to estimate the
effectiveness of certain therapies. At the same time, another possibility for future application
of miRNAs in therapy is the modulation of deregulated miRNAs concentration by molecules
that replace downregulated miRNAs or using antagonists that binds overexpressed miRNAs
[119]. Evidence supporting this possibility has been shown for the treatment of HCV infection;
this phase II clinical study is based on the treatment of HCV infected patients with Miravirsen
by which miR-122 is sequestered [120]. Miravirsen is the first miR-targeted drug to receive
Investigation New Drug (IND) acceptance from FDA [121]. To date, there is only one clinical
trial available in cancer patients; in particular, the treatment of liver cancer with MRX34, which
is a molecule mimicking miR-34, is ongoing, in order to evaluate its maximum tolerated dose
and its pharmacokinetics in patients [119].
4.6. TRAIL and Smac mimetics molecules
Recently, two classes of novel therapeutic agents targeting specific molecules involved in
apoptosis pathway have emerged. The first one is the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). It is able to induce cell death by binding to its corresponding cell
surface receptor TRAIL-R1/R2 and activating the apoptotic pathways [122-124]. A second class
of targeted anticancer agents is composed by Smac mimetics (SMs). They mimic the function
of endogenous proapoptotic mitochondrial protein Smac/Diablo [125]. In response to a death
stimulus, it is released in the cytoplasm and inhibits the antiapoptotic activity of IAP proteins
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[126]. Both TRAIL and SMs have been tested in several cancer models [123, 125, 127]. A study
testing the sensitivity to TRAIL and SMs treatment on HNSCC cell lines show that both
molecules are highly effective in killing tumor cells. In addition, caspase 8 and TNF-α expres‐
sion was identified as biomarker for predicting, respectively, TRAIL and SMs sensitivity [128].
These preliminary results encourage future investigations on the possibility to use them as
targeted HNSCC treatment.
4.7. Therapeutic activity of molecules derived from plants
Antineoplastic effects of molecules derived from plant extracts have recently gained increasing
attention as an additive to traditional therapies of cancer, including HNSCC.
One of  the most studied molecules derived from plants for HNSCC treatment is  curcu‐
min (diferuloylmethane). It is a polyphenol derived from the Curcuma longa plant, common‐
ly known as turmeric. Curcumin, which has been used extensively in Ayurvedic medicine
for centuries, is a pleiotropic molecule able to interact with multiple molecular targets and
signal transduction pathways, and has a variety of therapeutic properties, including anti-
oxidant, analgesic, anti-inflammatory and antiseptic activity [15]. More recently, curcumin
has  been  found  to  possess  anti-cancer  activities,  acting  on  several  biological  pathways
involved in mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigen‐
esis and metastasis [15]. For instance, it is able to inhibit the transcription factor NF-kB and
downstream gene products  (including c-myc,  bcl-2,  COX-2,  NOS,  cyclin D1,  TNF-alpha,
interleukins and MMP-9). Additionally, curcumin affects a variety of growth factor receptors
and cell adhesion molecules involved in tumor growth, angiogenesis and metastasis [15].
As a natural product, curcumin is no toxic. It is a potent antitumor agent also in HNSCC
and  can  be  used  to  overcome  chemoradiotherapy  resistance.  Indeed,  the  treatment  of
HNSCC cell lines with a molecule derived from curcumin (H-4073) inhibits cell prolifera‐
tion,  angiogenesis  and  significantly  sensitizes  the  cells  to  cisplatin  treatment.  H-4073
mediated its  antitumor effects  by inhibiting JAK/STAT3,  FAK,  Akt  and VEGF signaling
pathways that play important role in cell proliferation, migration, survival and angiogene‐
sis [129]. Another study shows that curcumin sensitizes to radiation HPV-negative HNSCC
cells with high levels of Thioredoxin reductase (TrxRs). Indeed, in this work it has been
demonstrated  that  the  efficacy  of  curcumin  in  sensitizing  tumor  cells  to  radiation  de‐
pends on its ability to inhibit TrxRd1. TrxRs are a family of NADPH-dependent flavopro‐
teins, which are involved in several redox-regulated cellular functions as transcription, DNA
repair, proliferation, angiogenesis and apoptosis. Specifically, high levels of TrxRd1 isoform
were found in HNSCC and were associated with poor outcome [130]. Finally, data from a
very recent study shows that curcumin is more effective, in terms of inhibition of cancer
growth, when combined with another non-flavonoid polyphenol called Resveratrol [131].
Another  intriguing  natural  anticancer  Chinese  medicine  is  Gamboge.  It  acts  as  anti-
inflammatory agent,  detoxifying and apoptotic  inducer  in  different  type  of  cancer  cells.
Interestingly,  the  Gamboge derivate  Compound 2  (C2)  is  able  to  inhibit  growth also  in
HNSCC  stem  cells.  Indeed,  it  can  inhibit  formation  of  tumor  spheres  and  repress  the
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expression  of  multiples  genes  related  to  cancer  stem  cell  phenotype  by  blocking  the
activation  of  EGFR pathways  [132].  Since  one  of  the  main  causes  of  failure  in  HNSCC
treatment is the enrichment of CSCs population, which are resistant to current therapy, the
future  use  of  this  molecule  in  combination  with  chemoradiotherapy  could  prevent  the
selective enrichment of CSCs after HNSCC conventional treatment.
5. Conclusions
Radioresistance strongly affects the clinical outcome of HNSCC patients. The key mechanisms
by which radioresistance occur have been associated with deregulation of several molecular
signaling pathways such as EGFR, VEGFR and p53. Recently, it has been shown that the
enrichment of a small population of tumor cells, named cancer stem cells, also plays an
important role in the failure of conventional HNSCC treatment. In addition, current treatments
are associated with high toxicity and side effects. The basis of treatment decisions are mainly
based on TNM staging, but patients with the same staging have different response to therapy.
Several molecular targeted therapies are actively under investigation in order to improve the
effectiveness of current therapy. Only a few of these strategies have been tested in clinical trials
and to date cetuximab is the unique targeted therapy approved from FDA. However, this
treatment showed efficacy in about 20% of HNSCC patients. In addition, due to the heteroge‐
neous nature of these tumors, the study of molecular prognostic and predictive factors has
been motivated by the necessity to predict radiosensitivity of patients and to define more
homogenous groups of patients for treatment selection. Indeed, personalized treatment plans
based on biomarkers could improve overall survival and reduce morbidity. Although several
evidences have shown that many molecules, as proteins and microRNAs, can potentially
predict response to therapy and clinical outcome, to date, the HNSCC treatment decision is
uniquely based on TNM staging and HPV infection. One of the reasons of the difficulties to
find efficacious biomarkers is the disagreement between these studies; this mainly relies on
the variety of tumor sites, sensitivity of the techniques used, quality of the specimens studied
and the arbitrary cut-off values set.
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